Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a series of chronic-phase CML patients who had previously been treated with interferon and who subsequently received imatinib mesylate, the appearance of myelosuppression (Grade > 3 neutropenia or thrombocytopenia) was associated with significantly less frequent major or complete cytogenetic responses.

The Significance of Imatinib Mesylate (Gleevec®)-Induced Cytopenias in Patients with Chronic-Phase CML